So­tio ter­mi­nates three tri­als study­ing its IL-15 su­per­ag­o­nist due to ‘in­suf­fi­cient ef­fi­ca­cy’

Czech biotech So­tio is im­me­di­ate­ly scrap­ping three clin­i­cal tri­als of its in­ter­leukin-15 su­per­ag­o­nist called nan­rilke­fusp al­fa af­ter in­ter­im da­ta showed “in­suf­fi­cient ef­fi­ca­cy.”
“While we are …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER